Identifying Dynamic Patterns of Polypharmacy for Patients with Dementia from Primary Care Electronic Health Records: A Machine Learning Driven Longitudinal Study

被引:3
作者
Longo, Elisabetta [1 ]
Burnett, Bruce [2 ]
Bauermeister, Sarah [3 ]
Zhou, Shang-Ming [4 ]
机构
[1] Aptuit, Via Alessandro Fleming 4, I-37135 Verona, Italy
[2] Swansea Univ, Inst Life Sci, Sch Med, Swansea SA2 8PP, Wales
[3] Univ Oxford, Dementias Platform UK, Dept Psychiat, Oxford OX3 7JX, England
[4] Univ Plymouth, Fac Hlth, Plymouth PL4 8AA, England
基金
英国医学研究理事会;
关键词
dementia; polypharmacy; patient safety; diagnosis; electronic health records; machine learning; exploratory factor analysis; RISK-FACTORS; PEOPLE; ASSOCIATION; PREVALENCE; DISEASE; COHORT;
D O I
10.14336/AD.2022.0829
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
It is unclear how medication use evolved before diagnosis of dementia (DoD). This study aims to identify varied patterns of polypharmacy before DoD, their prevalence and possible complications. We collected primary care e-health records for 33,451 dementia patients in Wales from 1990 to 2015. The medication uses in every 5-year period along with 20-years prior to dementia diagnosis were considered. Exploratory factor analysis was used to identify clusters of medicines for every 5-year period. The prevalence of patients taking three or more medications was 82.16%, 69.7%, 41.1% and 5.5% in the Period 1 (0-5 years before DoD) similar to Period 4 (16-20 years before DoD) respectively. The Period 1 showed 3 clusters of polypharmacy - medicines for respiratory/urinary infections, arthropathies and rheumatism, and cardio-vascular disease (CVD) (66.55%); medicines for infections, arthropathies and rheumatism (AR), cardio-metabolic disease (CMD) and depression (22.02%); and medicines for arthropathies, rheumatism and osteoarthritis (2.6%). The Period 2 showed 4 clusters of polypharmacy - medicines for infections, arthropathies, and CVD (69.7%); medicines for CVD and depression (3%); medicines for CMD and arthropathies (0.3%); and medicines for AR, and CVD (2,5%). The Period 3 showed 6 clusters of polypharmacy - medicines for infections, arthropathies, and CVD (41.1%); medicines for CVD, acute-respiratory-infection (ARI), and arthropathies (1.25%); medicines for AR (1.16%); medicines for depression, anxiety (0.06%); medicines for CMD (1.4%); and medicines for dermatologic disorders (0.9%). The Period 4 showed 3 main clusters of polypharmacy - medicines for infections, arthropathy, and CVD (5.5%); medicines for anxiety, ARI (2.4%); and medicines for ARI and CVD (2.1%). As the development towards dementia progressed, the associative diseases tended to cluster with a larger prevalence in each cluster. Farther away before DoD, the clusters of polypharmacy tended to be clearly distinct between each other, resulting in an increasing number of patterns, but in a smaller prevalence.
引用
收藏
页码:548 / 559
页数:12
相关论文
共 57 条
[1]   Effectiveness of interventions to directly support food and drink intake in people with dementia: systematic review and meta-analysis [J].
Abdelhamid, Asmaa ;
Bunn, Diane ;
Copley, Maddie ;
Cowap, Vicky ;
Dickinson, Angela ;
Gray, Lucy ;
Howe, Amanda ;
Killett, Anne ;
Lee, Jin ;
Li, Francesca ;
Poland, Fiona ;
Potter, John ;
Richardson, Kate ;
Smithard, David ;
Fox, Chris ;
Hooper, Lee .
BMC GERIATRICS, 2016, 16
[2]   Multi-Morbidity and Polypharmacy in Older People: Challenges and Opportunities for Clinical Practice [J].
Aggarwal, Pritti ;
Woolford, Stephen J. ;
Patel, Harnish P. .
GERIATRICS, 2020, 5 (04)
[3]  
Alzheimer's Society, 2021, RISK FACT DEM
[4]  
[Anonymous], 2015, Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes
[5]   Older patients are still under-represented in clinical trials of Alzheimer's disease [J].
Banzi, Rita ;
Camaioni, Paolo ;
Tettamanti, Mauro ;
Bertele, Vittorio ;
Lucca, Ugo .
ALZHEIMERS RESEARCH & THERAPY, 2016, 8
[6]   The Influence of Polypharmacy on the Initiation of Anti-Dementia Therapy in Germany [J].
Bohlken, Jens ;
Jacob, Louis ;
van den Bussche, Hendrik ;
Kostev, Karel .
JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 (03) :827-833
[7]   Polypharmacy Patterns: Unravelling Systematic Associations between Prescribed Medications [J].
Calderon-Larranaga, Amaia ;
Gimeno-Feliu, Luis A. ;
Gonzalez-Rubio, Francisca ;
Poblador-Plou, Beatriz ;
Lairla-San Jose, Maria ;
Abad-Diez, Jose M. ;
Poncel-Falco, Antonio ;
Prados-Torres, Alexandra .
PLOS ONE, 2013, 8 (12)
[8]   Association of Polypharmacy With Mild Cognitive Impairment and Cognitive Ability: A Nationwide Survey in Taiwan [J].
Cheng, Chih-Ming ;
Chang, Wen-Han ;
Chiu, Yu-Chuan ;
Sun, Yu ;
Lee, Huey-Jane ;
Tang, Li-Yu ;
Wang, Pei-Ning ;
Chiu, Ming-Jang ;
Yang, Cheng-Hung ;
Tsai, Shih-Jen ;
Tsai, Chia-Fen .
JOURNAL OF CLINICAL PSYCHIATRY, 2018, 79 (06)
[9]   Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data [J].
Clague, Fiona ;
Mercer, Stewart W. ;
McLean, Gary ;
Reynish, Emma ;
Guthrie, Bruce .
AGE AND AGEING, 2017, 46 (01) :33-39
[10]   'Timely' diagnosis of dementia: what does it mean? A narrative analysis of GPs' accounts [J].
Dhedhi, Saadia Aziz ;
Swinglehurst, Deborah ;
Russell, Jill .
BMJ OPEN, 2014, 4 (03)